Oncology & Cancer

No increase in seizure incidence with enzalutamide in mCRPC

(HealthDay)—For patients with metastatic castration-resistant prostate cancer (mCRPC) with at least one risk factor for seizure at baseline, treatment with enzalutamide is not associated with increased incidence of seizure, ...